DelveInsight added a report on the “Oropharyngeal Cancer Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Oropharyngeal Cancer. The launch of emerging therapies will significantly impact the Oropharyngeal Cancer market.

 

Oropharyngeal Cancer Overview

Oropharyngeal cancer is a type of head and neck cancer. Patients with oropharyngeal cancer related to HPV tend to present earlier in life as compared to those with tobacco-associated oropharyngeal cancer. The primary tumor is often difficult to see, hidden within the folds of the throat (tongue-base and tonsil.)

 

Get Sample Report @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market

 

Some of the key highlights of the Oropharyngeal Cancer Market Report

• Patient information website-Cancer.Net, rate of Oropharyngeal Cancer is more than twice as high in men as in women.
• Estimated number of Oral cavity & pharynx was near to 53,260 for 2020 (for both sexes).
• Approximately 29% of cancers involve the tongue and another 17% the lip. In addition to this, among pharyngeal sites, the oropharynx is the most common site for tumors (approximately 39%), followed by the hypopharynx (32%).
• Oropharyngeal Cancer companies such as Monopar Therapeutics, ISA Pharmaceuticals/ Regeneron Pharmaceuticals, and several others.
• Oropharyngeal Cancer therapies such as Validive, ISA101b plus Cemiplimab, and several others.

 

Oropharyngeal Cancer Symptoms

• Neck mass
• Difficulty or pain with swallowing
• Muffled voice
• Ear pain
• Throat pain or sore throat
• Lump or mass in the back of the throat

 

Oropharyngeal Cancer Prognostic Factors

There are few prognostic factors for oropharyngeal carcinoma such as

• HPV status
• Smoking history (pack-year smoking history of ten or more years)
• Tumor stage
• And nodal status

 

Oropharyngeal Cancer Treatment

Different treatments may be used either alone or in combination, depending on the stage and location of the tumor. In general, surgery is the first treatment for cancers of the oral cavity, and may be followed by radiation or combined chemotherapy and radiation. Oropharyngeal cancers are usually treated with a combination of chemotherapy and radiation.

 

Get an overview of the report @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market

 

Oropharyngeal Cancer Epidemiology Segmentation

• Total Incident cases
• Age-specific incident cases
• Total Diagnosed cases
• Treated Patient Pool cases
• Gender-specific incident cases

 

Oropharyngeal Cancer Market Insights

At present, there are several treatment choices for oropharyngeal cancer: surgery, radiation therapy, chemotherapy and targeted therapy. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemoradiation. Even after the surgery, cancer cell can be seen, therefore, few patients may be given chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

 

Oropharyngeal Cancer Emerging Therapies

• Radiotherapy
• Surgery
• Chemotherapy
• Upcoming Emerging Candidates
• Targeted Therapies

 

Oropharyngeal Cancer Emerging Therapy Assessment

The available therapeutics treatment options in Oropharyngeal Cancer Landscape aims to provide cure to the patients suffering from this indication, however there are several challenges which are yet to be tackled. The dynamics of the Oropharyngeal Cancer market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in development of drugs for Oropharyngeal Cancer. Key players, such as Precigen, and others are involved in developing drugs for Oropharyngeal Cancer.

 

Request Sample Report @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market

 

Oropharyngeal Cancer Market Report Scope

• Study Period- 2019-2032
• Coverage- The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• Key Companies: Monopar Therapeutics, ISA Pharmaceuticals/ Regeneron Pharmaceuticals, and several others.
• Key Therapies: Validive, ISA101b plus Cemiplimab, and several others.
• Unmet Needs
• KOL’s Views
• Market Drivers
• Market Barriers

 

Table of Content

1. Key Insights

2. Executive Summary of Oropharyngeal Cancer

3. Competitive Intelligence Analysis for Oropharyngeal Cancer

4. Oropharyngeal Cancer: Market Overview at a Glance

5. Oropharyngeal Cancer: Disease Background and Overview

6. Patient Journey

7. Oropharyngeal Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Oropharyngeal Cancer Unmet Needs

10. Key Endpoints of Oropharyngeal Cancer Treatment

11. Oropharyngeal Cancer Marketed Products

12. Oropharyngeal Cancer Emerging Therapies

13. Oropharyngeal Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Oropharyngeal Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/